创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

杜海洲. 国际治疗性肿瘤疫苗的开发与研究进展[J]. 药学进展, 2018, 42(9): 685-696.
引用本文: 杜海洲. 国际治疗性肿瘤疫苗的开发与研究进展[J]. 药学进展, 2018, 42(9): 685-696.
DU Haizhou. Progress in International Research and Development of Therapeutic Cancer Vaccine[J]. Progress in Pharmaceutical Sciences, 2018, 42(9): 685-696.
Citation: DU Haizhou. Progress in International Research and Development of Therapeutic Cancer Vaccine[J]. Progress in Pharmaceutical Sciences, 2018, 42(9): 685-696.

国际治疗性肿瘤疫苗的开发与研究进展

Progress in International Research and Development of Therapeutic Cancer Vaccine

  • 摘要: 肿瘤是全球人类第二大死因。一些肿瘤通常难以用像手术、放疗和化疗等常规治疗方法治疗,但可用肿瘤疫苗帮助刺激人体的免疫应答使其得到控制。将疫苗用于由诸如乙型肝炎病毒和人乳头瘤病毒(HPV)等致瘤病毒引起的感染现已非常成功地降低了这些感染导致的肿瘤发病率。治疗性肿瘤疫苗从免疫疗法兴起之初就给人们带来了很大的希望。尽管治疗性肿瘤疫苗在临床试验取得一些成功并有一种治疗前列腺肿瘤的疫苗获得批准,但大多数治疗性疫苗仍在临床试验之中。为了了解国际治疗性肿瘤疫苗的开发与研究现状,依据美国药物研究与生产商协会(PhRMA)最近发布的报告及临床试验数据库(Clinicaltrials.gov)与相关新药数据库中的数据,重点对进入Ⅲ期临床试验的3种抗原疫苗、3种肿瘤细胞疫苗、6种树突状细胞疫苗、5种核酸疫苗和2种其他治疗性肿瘤疫苗进行了分析和综述。分析结果表明,这19种肿瘤疫苗中许多在中期分析报告中,无论是在延长无复发生存率(RFS)和总生存率(OS)方面,还是在耐受性、安全性等方面,都显示出良好的开发前景。

     

    Abstract: Cancer is the second leading cause of death globally. Some tumors are refractory to conventional therapies such as surgery, radiotherapy, and chemotherapy, but can be controlled by using cancer vaccines to stimulate the body's immune response. The use of vaccines for preventing infections by oncogenic viruses such as hepatitis B virus (HBV) and human papilloma virus (HPV) has been extremely successful in reducing the incidence of cancers caused by these infections. Therapeutic cancer vaccines have brought great hope to people since the beginning of immunotherapy. Although there have been some successes in the clinical trials of therapeutic cancer vaccines and one cancer vaccine for the treatment of prostate cancer has been approved, most of them are still under clinical development. In order to understand the current status of international development and research of therapeutic cancer vaccines, 3 antigen (protein, peptide) vaccines, 3 tumor cell (autologous, allogenic) vaccines, 6 dendritic cell (DC) vaccines, 5 nucleic acid (DNA, RNA, viral vector) vaccines and 2 others that have entered phase Ⅲ clinical trial were mainly analyzed and reviewed according to the data from reports issued by the Pharmaceutical Research and Manufacturers of America (PhRMA), Clinicaltrials.gov and other related new drug databases. The analytical results indicated that many of the 19 thereapeutic cancer vaccines, according to their interim analysis reports, showed promising prospects in terms of prolonging relapse-free survival (RFS) and overall survival (OS) as well as tolerability and safety.

     

/

返回文章
返回